Innate Pharma (Euronext Paris: IPH) (Nasdaq: IPHA) announced on Monday progresses SAR443579 / IPH6101, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers.

The first patient dosing triggers a EUR4m milestone payment to Innate.

SAR443579, developed through a collaboration with Sanofi, targets high unmet needs in blood cancers like relapsed or refractory acute myeloid leukemia. The compound received FDA Fast Track Designation for acute myeloid leukemia treatment.

Under a 2016 collaboration agreement, Sanofi is responsible for development, manufacturing, and commercialization, with Innate eligible for up to €400m in milestone payments and royalties.

ANKET (Antibody-based NK cell Engager Therapeutics) platform by Innate creates multi-specific NK cell engagers for cancer treatment, offering a promising avenue in synthetic immunity against cancer.

Headquartered in Marseille, France, Innate Pharma develops immunotherapies for cancer patients, collaborating with industry leaders like Sanofi and AstraZeneca to accelerate innovation and research for patient benefit.